These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. P2Y12, a new platelet ADP receptor, target of clopidogrel. Herbert JM, Savi P. Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474 [Abstract] [Full Text] [Related]
6. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor. Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, Lassila R. Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433 [Abstract] [Full Text] [Related]
7. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Bhatt DL, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995 [Abstract] [Full Text] [Related]
11. Clopidogrel: a review of its use in the prevention of atherothrombosis. Jarvis B, Simpson K. Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738 [Abstract] [Full Text] [Related]
13. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Schleinitz MD, Weiss JP, Owens DK. Am J Med; 2004 Jun 15; 116(12):797-806. PubMed ID: 15178495 [Abstract] [Full Text] [Related]
14. Facts and controversies of aspirin and clopidogrel therapy. Faxon DP, Freedman JE. Am Heart J; 2009 Mar 15; 157(3):412-22. PubMed ID: 19249409 [Abstract] [Full Text] [Related]
15. P2Y receptor antagonists in thrombosis. Boeynaems JM, van Giezen H, Savi P, Herbert JM. Curr Opin Investig Drugs; 2005 Mar 15; 6(3):275-82. PubMed ID: 15816504 [Abstract] [Full Text] [Related]
16. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Am Heart J; 2009 Apr 15; 157(4):599-605. PubMed ID: 19332184 [Abstract] [Full Text] [Related]
19. Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes. Rodgers JE, Steinhubl SR. Expert Rev Cardiovasc Ther; 2003 Nov 15; 1(4):507-21. PubMed ID: 15030250 [Abstract] [Full Text] [Related]
20. Platelet P2Y12 receptor inhibition by thienopyridines: status and future. Porto I, Giubilato S, De Maria GL, Biasucci LM, Crea F. Expert Opin Investig Drugs; 2009 Sep 15; 18(9):1317-32. PubMed ID: 19678800 [Abstract] [Full Text] [Related] Page: [Next] [New Search]